These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities. Jendryczko A; Tomala J; Janosz P Zentralbl Gynakol; 1993; 115(11):469-72. PubMed ID: 8296490 [TBL] [Abstract][Full Text] [Related]
23. Observations with anteovin in family planning advisory unit. Domány Z Ther Hung; 1988; 36(1):29-33. PubMed ID: 3388289 [No Abstract] [Full Text] [Related]
24. [Systemic lupus erythematosus during therapy with oral estrogen-progestin. Considerations apropos of a case]. Gueli N; Toto A; Tartaglione E; Lucianetti MC; Screnci M; Sauli V; Carmenini G Clin Ter; 1987 May; 121(4):299-304. PubMed ID: 2973866 [No Abstract] [Full Text] [Related]
25. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. Creasy GW; Fisher AC; Hall N; Shangold GA J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776 [TBL] [Abstract][Full Text] [Related]
26. [Serum prolactin levels in women using oral contraceptives (Gravistat)]. Mikrut W; Jeske W Ginekol Pol; 1985 Oct; 56(10):620-3. PubMed ID: 4092990 [No Abstract] [Full Text] [Related]
27. [Paget-Schroetter syndrome caused by the use of oral contraceptives]. Steiner A; Millei J; Ján H; Erös L Orv Hetil; 1982 Sep; 123(39):2419-21. PubMed ID: 7145407 [No Abstract] [Full Text] [Related]
28. [Study of oral contraceptives action on blood folate levels (author's transl)]. Karlin R; Bourgeay M Pathol Biol (Paris); 1976 Apr; 24(4):251-5. PubMed ID: 778757 [TBL] [Abstract][Full Text] [Related]
29. [Morphologic changes in the epithelium of the uterine cervix in long-term administration of the 19-norsteroid-containing oral hormonal contraceptives Non-Ovlon and gravistat]. Geissler U Zentralbl Gynakol; 1988; 110(5):267-76. PubMed ID: 2453979 [TBL] [Abstract][Full Text] [Related]
30. [Risks of postcoital contraception using a d-norgestrel-ethinyl estradiol combination]. Welti H; Nguyen Duy N; Zufferey MM Ther Umsch; 1986 May; 43(5):438-40. PubMed ID: 3726780 [No Abstract] [Full Text] [Related]
35. Change to Tri-Regol from other oral contraceptives. Garamvölgyi G Ther Hung; 1991; 39(3):122-4. PubMed ID: 1818425 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of routine diabetes and lipid screening after age 35 in candidates for or current users of oral contraceptives. Kjos SL; Gregory K; Henry OA; Collins C Obstet Gynecol; 1993 Dec; 82(6):925-30. PubMed ID: 8233266 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of body composition during low-dose estrogen oral contraceptives treatment. Franchini M; Caruso C; Nigrelli S; Poggiali C Acta Eur Fertil; 1995; 26(2):69-73. PubMed ID: 9098463 [TBL] [Abstract][Full Text] [Related]
38. Early effect of a low dose (30 micrograms) ethinyl estradiol-containing Triphasil on vitamin B6 status. A follow-up study on six menstrual cycles. Massé PG; van den Berg H; Duguay C; Beaulieu G; Simard JM Int J Vitam Nutr Res; 1996; 66(1):46-54. PubMed ID: 8698546 [TBL] [Abstract][Full Text] [Related]
39. Results of the multilateral study of Tri-Regol tablet. Seregély G Ther Hung; 1991; 39(3):136-41. PubMed ID: 1840164 [TBL] [Abstract][Full Text] [Related]